PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway

The goal of this clinical trial is to compare treatment with oral Paxlovid (nirmatrelvir/ritonavir) and placebo for acute COVID-19 as an intervention to prevent long-COVID (post-COVID-19 condition) in adults aged 18-64 years old. The main question it aims to answer is: Does treatment with Paxlovid for acute COVID-19 reduce the prevalence of long-COVID compared to placebo. Participants with acute COVID-19, documented with positive lateral flow test or PCR, within the last 5 days will be randomised to take either Paxlovid or placebo. All participants will receive standard of care in addition. Participants will respond to electronic questionnaires at 14 time points during follow-up. The primary outcome is presence of long-COVID symptoms at 3 months follow-up. Researchers will compare participants who received Paxlovid and placebo to see if Paxlovid treatment can prevent the occurrence of long-COVID.

NCT Number	NCT05852873
Lead Sponsor	Haukeland University Hospital Collaborators: University of Bergen, Oslo University Hospital, University of Oslo, St. Olavs Hospital, Norwegian University of Science and Technology
Conditions	Post COVID-19 Condition, Unspecified, SARS-CoV2 Infection, COVID-19
Enrollment	2,000 participants
Start Date	2023-05-12
Primary Completion	2025-09-09 (estimated)
Study Completion	2027-06-11 (estimated)
Updated on ClinicalTrials.gov	2025-11-21